Anda di halaman 1dari 50

Centers for Education &

Research on Therapeutics

Blok Emergency/ TA 2014-2015

Interaksi obat
Dr. Risdawati Djohan, M.Kes.,Apt

Centers for Education &

Blok
Emergency/
TA 2014-2015
Research
on Therapeutics

Centers for Education &

Blok
Emergency/
TA 2014-2015
Research
on Therapeutics

Interaksi yang menguntungkan:


penisilin dengan probenesid, probenesid
menghambat sekresi penisilin di tubuli ginjal
kadar penisilin dalam plasma

efektivitasnya dalam
terapi gonore

kombinasi obat antihipertensi

meningkatkan efektivitas
dan mengurangi efek
samping

kombinasi obat antiasma

meningkatkan efektivitas

kombinasi obat antidiabetik

meningkatkan
efektivitas;

kombinasi antibiotik antipseudomonas

meningkatkan efektivitas

kombinasi obat antikanker

juga meningkatkan
efektivitas

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

kombinasi antibiotik
antipseudomonas

meningkatkan efektivitas

kombinasi obat antikanker

juga meningkatkan
efektivitas

kombinasi obat anti-HIV


a

memperlambat timbulnya
resistensi virus terhadap
obat

kombinasi obat antihepatitis

meningkatkan efektivitas

kombinasi obat untuk H. pylori

meningkatkan efektivitas

kombinasi antibiotik betalaktam


dengan penghambat penghambat
betalaktamase

meningkatkan efektivitas

kombinasi sulfametoksazol dengan


trimetoprim

meningkatkan efektivitas

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Faktor yang memudahkan terjadinya


interaksi obat: polifarmasi
Survei (1977)
insidens efek samping pada pasien dirawat di
rumah sakit karena polifarmasi :
3,5% pada pemberian 0-5 macam obat
54% pada pemberian 16-20 macam obat

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Interaksi obat penting secara klinik, jika


meningkatkan toksisitas dan/atau
mengurangi efektivitas terutama jika
menyangkut obat dengan batas keamanan yang
sempit (indeks terapi yang rendah atau slope log
DEC yang curam) misalnya:
glikosida jantung
antikoagulan
obat-obat sitostatik.

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Batas Keamanan
Dosis terapi median atau dosis efektif median
(=ED50): Dosis yang menimbulkan efek terapi
pada 50% individu disebut
Dosis letal median (=LD50): dosis yang
menimbulkan kematian pada 50% individu, atau
menimbulkan keracunan pada 50% individu
(dosis toksik 50% = TD50)
Dalam studi farmakodinamik di laboratorium,
indeks terapi suatu obat dinyatakan dalam rasio
berikut:

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Centers for Education &


Research on Therapeutics

Case 1: Torsades de Pointes

Monahan BP et al. JAMA 1990;264(21):27882790.

Centers for Education &


Research on Therapeutics

Ventricular Arrhythmia (Torsades de


Pointes) with Terfenadine Use
39-year-old female Rx with terfenadine 60
mg bid and cefaclor 250 mg tid 10 d
Self-medicated with ketoconazole 200 mg
bid for vaginal candidiasis
2-day Hx of intermittent syncope
Palpitations, syncope, torsades de pointes
(QTc 655 msec)

Monahan BP et al. JAMA 1990;264(21):27882790.

Centers for Education &


Research on Therapeutics

Symptomatic
Medroxyprogesterone

Ketoconazole

Cefaclor

Terfenadine

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Day of Administration
Monahan BP et al. JAMA 1990;264(21):27882790.

Centers for Education &


Research on Therapeutics

Case 2: Rhabdomyolysis

Adapted from: Sinoway L, Li J. J Appl Physiol 2005;99:522.

Centers for Education &


Research on Therapeutics

Rhabdomyolysis:
Atorvastatin & Fluconazole
76-year-old male with Hx of chronic atrial
fibrillation and aortic stenosis
Initial prescription medications:

Bisoprolol
Digoxin
Warfarin
Doxicycline
Fucidic acid

Prednisolone
Esomeprazole
Pravastatin
Fluconazole

Kahri J et al. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin
Pharmacol 2005;60:905907.

Centers for Education &


Research on Therapeutics

Rhabdomyolysis in Association with


Atorvastatin and Fluconazole Use
Pravastatin dosage increased from 40mg to
80mg/day
Pravastatin changed to Atorvastatin 40mg
After 7 days Extreme fatigue
After 3 weeks Hospitalized for dyspnea
Creatinine 1.36
CK 910 I.U.

Dx: Renal Failure and DEATH


Kahri J et al. Eur J Clin Pharmacol 2005;60:905907

Centers for Education &


Research on Therapeutics

Fatal Rhabdomyolysis
Death
Dyspnea & CK 910
Fatigue
Atorvastatin

Pravastatin 80mg

Pravastatin 40 mg

Fluconazole

Weeks

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Insidens interaksi obat sulit diperkirakan, k/


1. dokumentasi masih sangat kurang
2. seringkali lolos dari pengamatan dokter (k/ pemahaman
mekanisme dan kemungkinan terjadinya interaksi obat
kurang baik)
interaksi obat berupa peningkatan toksisitas reaksi idiosinkrasi

interaksi obat berupa penurunan efektivitas diduga akibat


bertambahnya keparahan penyakit
terlalu banyak obat yang saling berinteraksi sehingga sulit untuk

diingat

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

3. kejadian atau keparahan interaksi dipengaruhi oleh


variasi individual:
pasien lanjut usia
penyakit parah
kapasitas metabolisme
polimorfisme genetik
Penyakit tertentu:
gagal ginjal a/ penyakit hati yang kronik
penyakit jantung kongestif
faktor-faktor lain
dosis besar
obat ditelan bersama-sama
penggunaan obat bebas/suplemen/ herbal, merokok, dll.

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Istilah
Hiperreaktif efek dihasilkan pada dosis rendah sekali

Hiporeaktif efek dihasilkan pada dosis dosis tinggi


sekali
Hipersensitif efek yang berhubungan dengan alergi
obat.

Supersensitif keadaan hiperreaktif akibat denervasi atau


akibat pemberian kronik suatu bloker reseptor yang
merupakan denervasi farmakologik.
Toleransi keadaan hiporeaktif akibat pajanan obat
bersangkutan sebelumnya.

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Istilah
Takifilaksis atau toleransi akut toleransi yang terjadi
dengan cepat setelah pemberian hanya beberapa dosis
obat
Resisten Jika toleransi timbul akibat pembentukan
antibodi terhadap obat, misalnya terhadap insulin.

Idiosinkrasi istilah yang digunakan untuk efek obat


yang aneh (bizzare), ringan maupun berat, tidak
tergantung dari besarnya dosis, dan sangat jarang terjadi.
digunakan secara simpang siur istilah ini berubah menjadi
reaksi alergi obat atau akibat perbedaan genetik.

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Mekanisme interaksi obat


1. interaksi farmaseutik atau inkompatibilitas
(datap terjadi sebelumdan sesudah pemakaian obat)

2. interaksi farmakokinetik
GI tract
Plasma
Liver
Kidney

3. interaksi farmakodinamik
Dpt terjadi di organ target
Dpt terjadi sistemik ( misal tekanan darah)

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

INKOMPATIBILITAS
Terjadi di luar tubuh antara obat yang tidak
dapat dicampur (inkompatibel)
interaksi langsung secara fisik a/kimiawi
inaktivasi obat
pembentukan endapan
perubahan warna dan lain-lain
perubahan yang tidak terlihat

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

INKOMPATIBILITAS (lanjutan)
Interaksi farmaseutik yang penting (bagi seorang dokter):
interaksi antar obat suntik
interaksi antara obat suntik dengan cairan infus.
i-a antara obat dg obat a/ obat dg vehicle
Gentamisin + karbenisilin inaktivasi gentamisin
penisilin G + vitamin C inaktivasi penisilin G
amfoterisin B dlm lrt garam fisiologis a/lrt Ringer
amfoterisin B mengendap

fenitoin dalam larutan dekstrosa 5% fenitoin mengendap

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

INTERAKSI FARMAKOKINETIK

Salah satu obat mempengaruhi


Absorpsi
Distribusi
Metabolisme atau
Ekskresi
dari obat kedua,
kadar plasma obat kedua atau
Akibatnya: toksisitas atau efektivitas obat
Interaksi farmakokinetik tidak dapat diekstrapolasikan
ke obat

Centers for Education &


Research on Therapeutics

They Can Occur in the GI Tract


Sucralfate, some milk
products, antacids, and
oral iron preparations

Block absorption
of quinolones, tetracycline,
and azithromycin

Omeprazole,
lansoprazole,
H2-antagonists

Reduce absorption
of ketoconazole,
delavirdine

Didanosine (given
as a buffered tablet)

Reduces ketoconazole
absorption

Cholestyramine

Binds raloxifene,
thyroid hormone, and
digoxin

Centers for Education &


Research on Therapeutics

Interactions in the Plasma


To date, most protein bumping
interactions described are transient and
lack clinical relevance
The transient increase in free drug is
cleared more effectively

Centers for Education &


Research on Therapeutics

Spectrum of Consequences
of Drug Metabolism
Inactive products
Active metabolites
Similar to parent drug
More active than parent
New action unlike parent

Toxic metabolites

Centers for Education &


Research on Therapeutics

Microsomal Enzymes
Cytochrome P450
Flavin mono-oxygenase (FMO3)

Centers for Education &


Research on Therapeutics

Phases of Drug Metabolism


Phase I
Oxidation
Reduction
Hydrolysis

Phase II
Conjugation

Centers for Education &


Research on Therapeutics

Interactions Due to Drug Metabolism


Nearly always due to interaction with
Phase I enzymes, rather than Phase II
Commonly due to cytochrome P450
enzymes which have highly variable
activity and, in some cases, are
genetically absent or over-expressed

Centers for Education &


Research on Therapeutics

Phase I - Drug Oxidation

Centers for Education &


Research on Therapeutics

Cytochrome P450 Nomenclature,


e.g., for CYP2D6
CYP = cytochrome P450
2 = genetic family
D = genetic sub-family
6 = specific gene
NOTE: This nomenclature is genetically
based; it does not imply chemical specificity

Centers for Education &


Research on Therapeutics

Major Human CYP450 Isoforms

CYP1A2
CYP2B6
CYP2C8
CYP2C9
CYP2C19

CYP2D6
CYP2E1
CYP3A4
CYP3A5
CYP3A6

Centers for Education &


Research on Therapeutics

CYP450 Activity in the Liver


Relative Importance of
P450s in Drug Metabolism
CYP2E1

Relative Quantities
of P450s in Liver

CYP1A2

CYP2C

CYP1A2

CYP2C

CYP3A
CYP2D6

CYP2E1
CYP3A
CYP2D6

Shimada T et al. J Pharmacol Exp Ther 1994;270(1):414.

Centers for Education &


Research on Therapeutics

Polymorphic Distribution

Number of Subjects

Multiple groups of traits in which each


constitutes >1% of the population
91%

9%
PM

EM
Increasing Metabolic Capacity

URM

Centers for Education &


Research on Therapeutics

Cytochrome P450 3A
Responsible for metabolism of:
Most calcium channel blockers
Most benzodiazepines
Most HIV protease inhibitors
Most HMG-CoA-reductase inhibitors
Most non-sedating antihistamines
Cyclosporine

Present in GI tract and liver

Centers for Education &


Research on Therapeutics

CYP3A Inhibitors
Ketoconazole
Itraconazole
Fluconazole
Cimetidine
Clarithromycin
Erythromycin
Troleandomycin
Grapefruit juice

NOT Azithromycin

Centers for Education &


Research on Therapeutics

CYP3A Inducers
Carbamazepine
Rifampin
Rifabutin
Ritonavir
St. Johns Wort

Centers for Education &


Research on Therapeutics

Cytochrome P450 2D6


Absent in 7-9% of Caucasians,
12% of non-Caucasians
Over-expressed in up to 30% of East Africans
Catalyzes primary metabolism of:
Codeine
Many -blockers
Many tricyclic antidepressants

Inhibited by:
Fluoxetine
Paroxetine

Haloperidol
Quinidine

Aklillu E et al. J Pharmacol Exp Ther 1996;278(1):441 446.

Centers for Education &


Research on Therapeutics

Cytochrome P450 2C9


Absent in 1% of Caucasians and
African-Americans
Primary metabolism of:
Most NSAIDs (including COX-2)
S-warfarin (the active isomer)

Phenytoin

Inhibited by fluconazole

Centers for Education &


Research on Therapeutics

Cytochrome P450 2C19


Absent in 2030% of Asians,
35% of Caucasians

Primary metabolism of:


Diazepam
Omeprazole

Phenytoin
Clopidogrel

Inhibited by:
Omeprazole

Ketoconazole

Isoniazid

Centers for Education &


Research on Therapeutics

Cytochrome P450 1A2


Induced by smoking tobacco
Catalyzes primary metabolism of:
Theophylline
Propranolol

Imipramine
Clozapine

Inhibited by:
Many fluoroquinolone antibiotics
Fluvoxamine

Cimetidine

Centers for Education &


Research on Therapeutics

Drug Transporters
P-Glycoprotein and others
Pump drugs out of cells, which alters
distribution
Found in the following tissues:
Gut
Gonads
Kidneys
Biliary system
Brain (blood-brain barrier)
Placenta

Centers for Education &


Research on Therapeutics

P - Glycoprotein Tissue Distribution

Marchietti S, et al. Clinical relevance of drug-drug and herb-drug interactions mediated by the
ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 2007;12:927-41.

Centers for Education &


Research on Therapeutics

Digoxin and PGP


Digoxin is a PGP substrate
Increased digoxin plasma conc.
when combined with:
Quinidine
Talinolol
Erythromycin
Ritonavir

Verapamil
Clarithromycin
Itraconazole

Centers for Education &


Research on Therapeutics

Drug-Disease Interactions
Liver disease
Renal disease
Cardiac disease ( hepatic blood flow)
Acute myocardial infarction?
Acute viral infection?
Hypothyroidism or hyperthyroidism?

Centers for Education &


Research on Therapeutics

Grapefruit Juice and Felodipine

Hours after Dose

Dresser GK, et al. Clin Pharmacol Ther 2000;68(1):2834.

Hours after Dose

Centers for Education &


Research on Therapeutics

Drug-Herbal Interactions
St. Johns Wort with:
Indinavir
Cyclosporine
Digoxin
Tacrolimus
Possibly many others

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Centers for Education &


Research on Therapeutics

After St. Johns Wort

Centers for Education &


Research
on Therapeutics
Blok
Emergency/
TA 2014-2015

Terima kasih

Anda mungkin juga menyukai